The 2,000-Year Medical History of Agarikon Mushroom

Agarikon (Fomitopsis officinalis)

2,000+ years of documented medical use

A review of European medicinal polypores documents Fomitopsis officinalis (agarikon) as one of the five polypore species most widely used in central European folk medicine, applied for tuberculosis, coughs, asthma, rheumatism, and fever.

Grienke et al., Journal of Ethnopharmacology, 2014

~65 CE

first written record of agarikon as medicine, in Dioscorides' De Materia Medica

1 of 5

among the polypore species most widely used in central European folk medicine (Grienke review, 2014)

Old-growth

Fomitopsis officinalis depends on mature conifer forest; larch-forest loss drove its European decline

Grienke et al., Journal of Ethnopharmacology, 2014

View as image ↗

Around 65 CE, a Greek physician named Dioscorides documented a treatment for consumption (the disease we now call tuberculosis) in a multi-volume pharmacopoeia that would become the foundational medical reference in Europe for the next fifteen centuries. The remedy was a large bracket fungus from conifer trees called agarikon. That early documentation makes agarikon mushroom one of the oldest named medicines in the Western record, and the question Dioscorides couldn't answer was why it worked. Modern chemistry now has part of the answer. This article covers the full arc of that agarikon mushroom history: from the Greek pharmacopoeia to its near-disappearance from European forests, and what that 2,000-year record means in light of current research. For a broader overview of what agarikon is and the evidence for its bioactive properties, see What Is Agarikon? The Ancient Antiviral Mushroom.

The 2,000-Year Timeline: From Ancient Greece to Clinical Trial

The medical history of agarikon runs across four distinct periods, each separated by gaps in the written record but connected by the consistent appearance of the same mushroom for respiratory and infectious disease applications.

~65 CE. Dioscorides, a Greek physician serving in the Roman army, completes De Materia Medica. Agarikon appears as a treatment for consumption, respiratory complaints, and infectious disease. The text becomes the medical reference standard across the Mediterranean world and later medieval Europe.

Medieval period. European physicians and apothecaries document agarikon use for tuberculosis, coughs, asthma, rheumatism, and fever in herbals and pharmacopoeias drawing on the Dioscorides framework. The ethnobotanical record across this period is fragmentary but consistent: agarikon appears repeatedly for respiratory disease.

16th–19th centuries. Commercial collection for the European TB remedy market strips agarikon from most of its native range as old-growth forests are felled. By the late 19th century the mushroom is effectively extinct across most of its former European territory. Its medicinal use fades as pharmaceutical treatments for TB emerge.

1980s onward. Mycologist Paul Stamets begins systematic tissue banking of agarikon strains from old-growth conifer forests of the Pacific Northwest, preserving the genetic diversity of one of the species' last significant populations. Later laboratory screening of agarikon's compounds brings the mushroom back into scientific discussion.

This tradition is documented in the ethnobotanical literature by Grienke and colleagues (2014), whose review of European medicinal polypores is among the most comprehensive.^[1] Their review identifies Fomitopsis officinalis as one of five polypore species widely used in central European folk medicine, alongside Laetiporus sulphureus, Fomes fomentarius, Fomitopsis pinicola, and Piptoporus betulinus.

One Mushroom, Twenty Centuries

Agarikon: From Ancient Cough Remedy to Modern Chemistry

The documented path of Fomitopsis officinalis — from Dioscorides’ c. 65 CE record, through European folk medicine and the collapse of its old-growth host forests, to the modern chemical and review literature.

Traditional RecordHabitat & DeclineModern Science

1. c. 65 CETraditional Record

   Dioscorides records agarikon

   The Greek physician Dioscorides documents agarikon in De Materia Medica for consumption (tuberculosis), coughs, and other respiratory and infectious complaints — one of the earliest written records of a medicinal mushroom in the Western tradition.

2. Medieval–18th C.Traditional Record

   European folk medicine

   Agarikon persists across central European folk medicine for tuberculosis, coughs, asthma, rheumatism, and fever. A modern review of European medicinal polypores counts it among the five species most widely used in the tradition.

3. 18th–19th C.Habitat & Decline

   Mass-collection and decline

   Fomitopsis officinalis is mass-collected for 18th- and 19th-century pharmacy while heavy demand for larch timber and resin strips its host forests. The combined pressure drives the fungus toward disappearance across much of its European range.

4. 2013Modern Science

   A chemical clue for the TB use

   Chemists isolate two chlorinated coumarins from F. officinalis with a narrow antimicrobial spectrum and the lowest MICs against the Mycobacterium tuberculosis complex — an in vitro hint at why the ancient TB remedy was used, not clinical proof.

5. 2020–2025Modern Science

   Modern reviews and conservation

   Review papers catalogue the fungus's coumarins, phenolics, polysaccharides, terpenoids, and sterols and their antibacterial, antiviral, anti-inflammatory, anticancer, and antioxidant activity — while flagging overexploitation and habitat loss as an urgent conservation problem.

European folk-medicine use and the five-polypore ranking per Grienke et al., Journal of Ethnopharmacology, 2014. Pharmacy history and larch-forest decline per Muszyńska et al., Chemistry & Biodiversity, 2020. Chlorinated-coumarin anti-TB activity per Hwang et al., Journal of Natural Products, 2013 (in vitro). Bioactive profile and conservation status per Gafforov et al., Plant Foods for Human Nutrition, 2025. The c. 65 CE Dioscorides entry is a documented historical record, not a clinical result.

What Dioscorides Actually Said (and What He Couldn't Explain)

Dioscorides' De Materia Medica, written around 65 CE, is the starting point for most accounts of agarikon's history. But those accounts rarely examine what the text actually records.

Dioscorides documented agarikon primarily for consumption, which in the ancient world referred to the progressive wasting disease we now identify as pulmonary tuberculosis. He also listed applications for spitting of blood, asthma, liver pain, and febrile conditions. The description is practical: specific conditions, a named remedy, and implicit dosing notes through the preparation method. This is not myth. It is a clinical record, however limited by the diagnostic and chemical knowledge of the era.

What Dioscorides could not have known is that he was describing a mushroom that produces chlorinated coumarin compounds with measurable activity against the tuberculosis bacterium, as Hwang and colleagues would report in 2013.^[4] He observed the clinical correlation over centuries of empirical use. The chemistry behind that correlation took another two thousand years to identify.

The 2025 review by Gafforov et al. in Plant Foods for Human Nutrition provides a current summary of the documented chemical profile that corresponds to the historical therapeutic claims.^[2] The fungus is a rich source of coumarin derivatives, phenolic compounds, polysaccharides, terpenoids, and sterols. These compound classes show antibacterial, antiviral, anti-inflammatory, anticancer, and antioxidant activity in laboratory studies, and those activities align, at least partially, with the conditions for which agarikon was historically used.

Why TB? The Chemistry That Explains the Ancient Remedy

Of all the traditional applications for agarikon, tuberculosis treatment is the most historically significant and the most chemically interesting.

Tuberculosis remains one of the world's deadliest infectious diseases, and the rise of drug-resistant strains has made the search for new antitubercular compounds a global research priority. That search increasingly revisits natural products, including compounds from fungi, in the hope of finding chemistry that conventional antibiotics do not provide. Agarikon's long traditional use against consumption made it an obvious candidate to examine in the laboratory.

Hwang et al. (2013) isolated two naturally occurring chlorinated coumarins from Fomitopsis officinalis and tested their antimicrobial activity.^[4] The compounds showed a narrow spectrum of activity, with their lowest minimum inhibitory concentrations (MICs, the lowest concentration that stops visible bacterial growth) recorded against the Mycobacterium tuberculosis complex. Put simply, of the microbes tested, the tuberculosis bacterium was the one these agarikon compounds inhibited most potently.

This finding doesn't validate Dioscorides' claim that agarikon cures tuberculosis. The in vitro finding against cultured bacteria is not clinical evidence. But it does something important for how we read the historical record: it provides a plausible chemical basis for why empirical observation across many centuries and many cultures pointed to the same fungus for the same disease. The people using agarikon for consumption may well have been observing real effects from real chemistry, even without the tools to explain it.

The 2020 review by Muszyńska and colleagues places this antitubercular activity in the context of agarikon's full bioactive profile, noting that its several compound classes — triterpenoids, polysaccharides, organic acids, coumarins, and phenolics — carry a range of antimicrobial and anti-inflammatory activities.^[3] The breadth of the historical applications may reflect this chemical diversity: different compounds reaching different targets.

For detailed coverage of how agarikon's antiviral compounds work against influenza and herpes in modern laboratory research, see Agarikon and Antiviral Activity: Influenza and Herpes Research.

European Traditional Medicine Beyond Tuberculosis

Grienke and colleagues' 2014 review of European medicinal polypores documents what European traditional cultures used agarikon for, drawing on the ethnobotanical and phytochemical literature.^[1]

The review documents applications well beyond tuberculosis. Across central European folk medicine, agarikon and the other widely used polypores appear for coughs, asthma, rheumatism, and pyretic (fever) conditions, and in some records for complaints such as dysmenorrhoea, haemorrhoids, and bladder disorders.

What is notable in the ethnobotanical record is a degree of geographic consistency: the same fungus, applied to overlapping sets of conditions, across cultures whose main documented connection is the shared presence of the mushroom in their environment. This pattern is often read as a sign that the observed effects were real rather than purely cultural transmission of a Dioscorides-derived reputation.

Grienke and colleagues drew their conclusions from a structured survey of the literature rather than a narrative compilation of anecdotes, searching scientific databases to assemble the traditional uses, chemistry, and biological activity of the major European medicinal polypores. That approach is what lets agarikon's place in the tradition be described with some confidence rather than treated as folklore.

Pacific Northwest Indigenous Use: What's Actually Documented

The Pacific Northwest populations of agarikon, growing on old-growth Douglas fir and hemlock, overlap with the traditional territories of multiple Indigenous peoples including the Haida and other Northwest Coast nations.

There is documented traditional use of bracket fungi by Northwest Coast peoples in ethnobotanical records, and agarikon's presence in these forests is well established. However, the specific claims about Indigenous use of agarikon that circulated in popular accounts of the mushroom's history (particularly claims about its use to protect against European smallpox) have been subject to significant revision.

The ethnobotanical record for Pacific Northwest Indigenous use of Fomitopsis officinalis specifically is incompletely documented compared to the European record. Grienke and colleagues' review focused on European sources, and no equivalent systematic analysis of Pacific Northwest Indigenous uses of this specific species appears in the peer-reviewed literature covered by this brief.^[1] What is known is that bracket fungi were used medicinally across Northwest Coast cultures; what specific uses applied to agarikon specifically requires more careful sourcing than popular accounts have provided.

Near-Extinction: Why the 2,000-Year Remedy Almost Vanished

Agarikon's survival depends on a single condition that the modern world has made increasingly rare: old-growth conifer forest.

Fomitopsis officinalis grows almost exclusively on living or recently dead conifers — primarily larch in Europe and Central Asia, Douglas fir and hemlock in the Pacific Northwest — and favors old, established trees over young or second-growth stands. According to the 2020 review by Muszyńska and colleagues, the fungus's reliance on mature larch forests, combined with heavy demand for larch timber and resin, directly contributed to its disappearance from much of its natural European range.^[3]

This dependence on old forest made agarikon's European fate inseparable from the fate of those forests. Industrial-era logging removed the ancient larch stands of Central Europe and Central Asia that had supported agarikon populations for centuries. As Muszyńska and colleagues note, that exploitation drove the fungus from most of its former European range.

The conservation status is now a serious concern. The 2025 Gafforov review frames it as a pressing priority, discussing sustainable strategies such as establishing culture collections to preserve the species and its bioactive compounds in the face of overexploitation and habitat loss.^[2]

The Pacific Northwest became, by attrition, the world's most significant remaining reservoir of agarikon diversity. That is why the American strain-banking effort of recent decades matters: it preserves genetic material that Europe no longer has in the wild.

For the full story of the modern conservation and research effort, see Agarikon and Paul Stamets: The Quest to Save an Endangered Mushroom.

What Modern Chemistry Reveals About Agarikon Mushroom History

The most important shift in understanding agarikon's medical history over the past two decades is not the discovery of new data. It is the ability to connect the historical applications to specific compounds and mechanisms.

The 2025 Gafforov review synthesizes the current state of this connection.^[2] Agarikon's terpenoids and sterols, coumarins, phenolics, and polysaccharides have shown antibacterial, antiviral, anti-inflammatory, anticancer, and antioxidant activity in laboratory work. The chlorinated coumarins, as Hwang and colleagues (2013) showed, were most active against the tuberculosis bacterium.^[4] Its polysaccharide fraction — like the beta-glucans common to medicinal mushrooms — is associated with immune-modulating and anti-inflammatory effects.

Each of these compound classes corresponds to a category of traditional applications. Antibacterial and antitubercular activity for the TB and infection uses. Anti-inflammatory compounds for the rheumatic and fever applications. Immune-modulating polysaccharides for the general strengthening properties described in the traditional literature. The correspondence is not perfect, and this is not a validation of every historical claim. But the pattern is coherent: the 2,000-year empirical record was pointing at real chemistry.

What remains genuinely uncertain is the clinical translation. Moving from isolated compound activity in cell culture to meaningful effects in humans requires the kind of controlled clinical trials that barely exist for agarikon. The historical record tells us the mushroom was observed to do something useful, and the chemistry tells us plausible mechanisms. What it cannot tell us is effective dose, optimal preparation method, or which specific applications translate from tradition to modern clinical use.

For the current state of the antiviral research and what the evidence actually supports, see Agarikon and Paul Stamets' Antiviral Hypothesis: What the Research Actually Shows.

The Bottom Line

Agarikon's 2,000-year documented medical history is anchored by Dioscorides' first-century record and carried forward in Grienke and colleagues' 2014 review of European medicinal polypores, which counts it among the five species most widely used in central European folk medicine. The traditional use for tuberculosis has a plausible chemical basis: Hwang et al. (2013) isolated chlorinated coumarin compounds from agarikon whose lowest minimum inhibitory concentrations, in vitro, fell against the Mycobacterium tuberculosis complex. That long record is now at risk: heavy exploitation of its old larch host forests drove agarikon from most of its former European range, leaving the Pacific Northwest as a primary surviving habitat and making active strain preservation an urgent conservation priority.

Frequently Asked Questions

What did Dioscorides say about agarikon?

Dioscorides documented agarikon around 65 CE in De Materia Medica as a treatment for consumption (tuberculosis), spitting of blood, asthma, and liver pain. His account is one of the earliest written records of a medicinal mushroom in the Western tradition, and Grienke and colleagues' 2014 review of European medicinal polypores treats it as a foundational reference for agarikon's documented use, a record that held across many centuries of subsequent medical literature.

What did ancient Greeks use agarikon to treat?

Ancient Greek medical texts, primarily through Dioscorides, document agarikon for consumption (tuberculosis), coughs, asthma, blood-spitting, and febrile conditions. The applications were primarily respiratory and infectious in character. These uses persisted into medieval European medicine through the Dioscorides tradition, appearing in herbals and pharmacopoeias across multiple centuries. Grienke and colleagues' 2014 review of European medicinal polypores records tuberculosis and respiratory complaints among the most consistently documented applications.

When was agarikon first mentioned in medicine?

The earliest documented medical reference is Dioscorides' De Materia Medica, written around 65 CE. This makes agarikon one of the oldest named medicinal mushrooms in the Western record, though its use almost certainly predates written documentation. The 2025 review by Gafforov et al. in Plant Foods for Human Nutrition provides a current synthesis of agarikon's traditional uses and chemistry, noting its long use in European medicine for pulmonary conditions such as asthma, pneumonia, and tuberculosis.

Why did people use agarikon for tuberculosis?

Empirical observation over many centuries converged on agarikon for tuberculosis before any chemical explanation existed. A chemical clue came in 2013, when Hwang et al. isolated two chlorinated coumarins from Fomitopsis officinalis and found their lowest minimum inhibitory concentrations fell against the Mycobacterium tuberculosis complex — that is, of the microbes tested, the TB bacterium was the one they inhibited most potently. This is an in vitro finding, not clinical evidence, but it offers a plausible chemical basis for why the traditional remedy was observed to help.

How did Native Americans use agarikon mushroom?

Agarikon grows across old-growth conifer forests of the Pacific Northwest, which overlaps with the traditional territories of multiple Indigenous nations including the Haida. Bracket fungi are documented in Northwest Coast Indigenous ethnobotanical records for various medicinal applications. However, the specific documented traditional uses of Fomitopsis officinalis (as distinct from bracket fungi generally) in Pacific Northwest Indigenous medicine are incompletely recorded in the peer-reviewed ethnobotanical literature. Popular accounts of its use in this context require more careful sourcing than they have typically received.

Sources & References

1. 1RTHM-00322·Grienke, Ulrike et al. (2014). “European medicinal polypores--a modern view on traditional uses..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00924·Gafforov, Yusufjon et al. (2025). “Mycochemistry, Traditional Uses, and Nutraceutical Potential of Laricifomes officinalis: A Biotechnological and Pharmacological Perspective..” Plant foods for human nutrition (Dordrecht.Study breakdown →PubMed →↩
3. 3RTHM-00640·Muszyńska, Bożena et al. (2020). “Fomitopsis officinalis: a Species of Arboreal Mushroom with Promising Biological and Medicinal Properties..” Chemistry & biodiversity.Study breakdown →PubMed →↩
4. 4RTHM-00290·Hwang, Chang Hwa et al. (2013). “Chlorinated coumarins from the polypore mushroom Fomitopsis officinalis and their activity against Mycobacterium tuberculosis..” Journal of natural products.Study breakdown →PubMed →↩